Navigation Links
Health Canada approves cold and flu medicine

Health Canada, the Canadian government regulatory agency, has approved wide-ranging new health claims for COLD-fX®, the most popular cold/flu remedy in Canada. After an extensive review, the Natural Health Products Directorate (NHPD) ?a division of Health Canada responsible for evaluating the safety, efficacy and quality of natural health products (NHPs) ?has issued COLD-fX with a much sought after license to sell to the public with specific science backed claims.

The comprehensive treatment claim for COLD-fX® approved by Health Canada states that the product “helps reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system.? Comprehensive therapeutic claims require support by the highest level of scientific evidence: randomized, double-blind, placebo-controlled clinical trials.

“This is our strongest point of medical recognition to date, and coming from the government authority whose responsibility it is to help Canadians maintain and improve their health, this approval should give great confidence to consumers,?said Dr. Jacqueline Shan, co-founder of CV Technologies, a University of Alberta spinoff company that developed COLD-fX.

Shan, who is also president, CEO and Chief Scientific Officer of CV Technologies added, “There are two novel therapeutic aspects to COLD-fX. First, COLD-fX is one of the very few medicines ?drugs or natural health products ?that Health Canada has approved for daily use as a preventative medicine. Second, COLD-fX can be taken to provide symptom relief for colds and flu."

Shan added that Health Canada reviewed all of CV Technologies published and unpublished data on COLD-fx before approving the claims.

The NHPD issues product licenses in several categories. Because COLD-fX® is a unique patented product, it was issued an NPN in the non-traditional category, which requires the highest level of scientific evidence. In contrast, claims with the term “tra ditional?are not based on scientific evidence and products in the "monograph" category have claims which are not supported by specific research on their particular product.

“There’s no cure for the common cold,?Dr. Shan stated. “So, in medicine the traditional strategy is if you can’t treat the disease, you treat the symptoms. The COLD-fX strategy is to boost your immune system to help you avoid getting a cold or the flu in the first place, or if you do get one, to fight it more effectively."

The NHPD’s safety review confirmed the safety profile of COLD-fX with no known side effects or drug interactions for generally healthy individuals.

Health Canada established new regulations effective Jan. 1, 2004, to monitor and manage the NHP industry. CV Technologies was the first company in Canada to launch and complete a trial under the new regulations. These regulations are being phased in over a six-year period as the NHPD reviews supporting safety, efficacy and quality information for all natural health products.

Although there are grey areas between the definitions of drugs and natural health products in general, the major distinction is that natural health products are derived from natural sources. Natural health products require the same degree of scientific evidence as drugs to support their claims. Natural health product regulations are also similar to drug regulations with requirements for standardized labeling, good manufacturing practices, and specification requirements for finished products and post-market surveillance for potential adverse effects.


'"/>

Source:University of Alberta


Related biology news :

1. BioMed Central welcomes the new National Institutes of Health public access policy
2. OneWorld Health drug receives Orphan designation from U.S. and European regulatory agencies
3. Health costs soar as 60 million Americans classed as obese
4. Going To Extremes To Improve Human Health
5. Patient-choice C-section rate rises 36%: HealthGrades study
6. Grand Challenges in Global Health initiative funds Yale project
7. Health benefits of a Christmas brandy
8. Health of coral reefs detected from orbit
9. Health of Acehnese reefs in the wake of the tsunami shows human impacts more harmful
10. Healthy coral reefs of Madagascar resisting damage from climate change
11. Mailman School of Public Health researchers report blood DNA can be early predictor of liver cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
(Date:1/13/2016)... January 13, 2016 ... addition of the  "India Biometrics Authentication ... Forecast (2015-2020)"  report to their ... has announced the addition of the  ... - Estimation & Forecast (2015-2020)" ...
(Date:1/7/2016)... This BCC Research report studies the global ... devices, identifying newer markets and exploring the expansion of ... devices. Includes forecast from 2015 to 2020. ... explore the expansion of the present application market for ... biometric technology, determine its current market size, and estimate ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... Stockton has an active R&D program for the ... area, the Group has a unique research and development center ... in developing Bio Control products. Stockton ... parameters and regulatory guidelines, and is active in more than ... Stockton,s flagship product Timorex Gold ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... The Center for Excellence in Education Sponsors Teacher Training Program , Bite of ... 2016 – The Center for Excellence in Education (CEE) will sponsor a Bite ...
(Date:2/5/2016)... Amarantus BioScience Holdings, Inc. ... developing products for Regenerative Medicine, Neurology and Orphan Diseases, ... (RPDD) from the US Food and Drug Administration (FDA) ... previously granted orphan drug designation (ODD) by the US ... Holdings, Inc. (OTCQB: AMBS), a biotechnology ...
(Date:2/4/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... Edward Lanphier , Sangamo,s president and chief executive officer, ... ZFP Therapeutic ® development programs and an overview ... on Thursday, February 11, 2016, at the Leerink Partners ... is being held in New York ...
Breaking Biology Technology: